Exploring PLX-4545: A Novel Molecular Glue Targeting IKZF2 for Neoplasm Treatment

PLX-4545 is a molecular glue drug developed by Plexium, Inc. The drug targets IKZF2 and is intended for the treatment of neoplasms. Currently, PLX-4545 is in Phase 1 of development, indicating that it is still undergoing initial testing for safety and efficacy.

As a molecular glue, PLX-4545 likely works by binding to specific proteins and altering their function, potentially leading to therapeutic effects in neoplasms. IKZF2, the target of the drug, is a protein that plays a role in the regulation of gene expression and has been implicated in various types of cancer. By targeting IKZF2, PLX-4545 has the potential to impact the growth and proliferation of cancer cells.

Neoplasms, or tumors, are abnormal growths of tissue that can be benign or malignant. The fact that PLX-4545 is designed to specifically target neoplasms suggests that it may have a more targeted approach to treating cancer, with potentially fewer side effects compared to traditional chemotherapy or radiation therapy.

As the originator organization, Plexium, Inc. is responsible for the development and eventual commercialization of PLX-4545. They will oversee the clinical trials and regulatory approvals necessary to bring the drug to market.

Below, we will use the drug PLX-4545 as an example to demonstrate how to quickly obtain information about its chemical structure and patent situation using the Patsnap Chemical.

Log in to the Patsnap Chemical. Select the structural search and enter the common identity information of PLX-4545(such as CAS number, generic substance name, molecular formula, SMILES file, etc.). Here, using a similarity search (setting the Tanimoto coefficient to 0.8), check the box for manual curation, click on search structures, and you can find the innovative drug PLX-4545, as disclosed in the patent application with the publication number WO2023283425A1, first made public on 2023-01-12.

There are 41 patents related to this compound. Clicking the "view in Analytics" will direct you to the Patsnap Patent.

Among the applicants of the patent, we can find other companies' fast follow patents on Plexium, Inc.; for example, WO2023122615A1 (with an application date of 2022-12-20) is a compound patent application from GILEAD SCIENCES, INC., which is currently under substantive examination. The patent text describes compounds that can bind and degrade a protein called IKAROS Family Zinc Finger (IKZF) 2 (Helios). Additionally, the international application WO2024140638A1 of GLUETACS THERAPEUTICS (SHANGHAI) CO LTD was published on 2024-07-04. The patent has entered China(patent publication number CN118556048A) and is currently under substantive examination.

Overall, the information provided indicates that PLX-4545 is a promising candidate in the field of biomedicine for the treatment of neoplasms. Its specific targeting of IKZF2 and its molecular glue mechanism of action may offer a novel approach to addressing cancer. However, it is important to note that PLX-4545 is still in the early stages of development, and further research will be necessary to determine its safety and efficacy in treating neoplasms.

AI built to maximize IP and R&D efficiency

Redefine chemical FTO with a range of structure retrieval options at your fingertips, from exact matches to similarity searches, all powered by deep data processing techniques and proprietary AI algorithms to eliminate the risk of omitting key results.